The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investee Company Update: Nuuvera Inc.

23 Mar 2018 15:35

RNS Number : 8171I
FastForward Innovations Limited
23 March 2018
 

 

23 March 2018

 

FastForward Innovations Limited

("FastForward"")

Investee Company Update: NUUVERA INC.

COMPLETION OF PLAN OF ARRANGEMENT WITH APHIRA INC.

FastForward notes the announcement today by investee company Nuuvera Inc. ("Nuuvera" (TSXV: NUU)), a public company formed to capitalize on the global trend towards the legalisation of medical cannabis, in which FastForward currently has a holding of 3 million shares or 3.4%. The announcement is set out below without material changes or adjustments:

LEAMINGTON and TORONTO, ON , March 23, 2018 /CNW/ - Aphria Inc. ("Aphria") (TSX:APH and US OTC: APHQF) and Nuuvera Inc. ("Nuuvera") (NUU.V) are pleased to announce that they have completed the previously announced arrangement (the "Arrangement") under the provisions of the Business Corporations Act ( Ontario ), pursuant to which, among other things, Aphria has acquired all of the common shares of Nuuvera (the "Nuuvera Shares") not already owned by it.

Under the terms of the Arrangement, each former Nuuvera shareholder is now entitled to receive $0.62 in cash, rather than $0.60 , as previously announced, plus 0.3546 of a common share of Aphria, for each Nuuvera Share held prior to the Arrangement (the "Consideration"). The increase in the cash consideration is a result of Nuuvera's cash on hand exceeding the Restricted Cash Amount (as defined in the Arrangement Agreement Amending Agreement dated February 19 , 2018). 

It is anticipated that the Nuuvera Shares will be delisted from the TSX Venture Exchange as of the close of trading on or about March 26, 2018 and Nuuvera intends to submit an application to the applicable securities regulators to cease to be a reporting issuer and to terminate its public reporting obligations.

Pursuant to the letter of transmittal mailed to Nuuvera shareholders as part of the material in connection with the special meeting of Nuuvera shareholders held on March 20, 2018 (the "Meeting"), in order to receive the Consideration to which they are entitled, registered holders of Nuuvera Shares will be required to deposit their share certificate(s) representing Nuuvera Shares, together with the duly completed letter of transmittal, with TSX Trust Company, the depositary under the Arrangement. Shareholders whose Nuuvera Shares are registered in the name of a broker, dealer, bank, trust company or other nominee should contact their nominee with questions regarding the receipt of the Consideration.

Further information about the Arrangement is set forth in the materials prepared by Nuuvera in respect of the Meeting which were mailed to Nuuvera shareholders and filed under Nuuvera's profile on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

About Aphria

Aphria, one of Canada's lowest-cost medical cannabis producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario , the greenhouse capital of Canada , Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

For more information about Aphria, please visit www.aphria.ca

About Nuuvera

Nuuvera is a global cannabis company founded on Canadian principles, and built with the whole world in mind. Nuuvera is currently working with partners in Germany , Israel and Italy , and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets. Through its subsidiaries, ARA - Avanti and Avalon Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the Narcotic Control Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health Canada review process to become a Licensed Producer of medical marijuana under the ACMPR, and has recently received its "letter to build" approval.

For more information about Nuuvera, please visit: www.nuuvera.com

 

CONTACTS:

 

FastForward Innovations Limited info@fstfwd.co

Ed McDermott/ Sue Saunders/ Ian Burns

Beaumont Cornish Limited (Nomad) Tel: +44 (0) 207 628 3396

James Biddle / Roland Cornish

Optiva Securities Limited (Broker) Tel: +44 (0) 203 411 1881

Graham Dickson

CAUTIONARY STATEMENT

The AIM Market of London Stock Exchange plc does not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of FastForward Innovations Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognizable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. FastForward Innovations assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBUGDXSXDBGIX
Date   Source Headline
6th Apr 20167:00 amRNSInvestee Company Update
5th Apr 20162:50 pmRNSInvestee Company Update
4th Apr 20167:00 amRNSInvestee Company Update: Schoold
31st Mar 20161:18 pmRNSInvestee Company Update
9th Mar 201610:00 amRNSExpected announcement date of 2016 Final Results
4th Mar 201610:01 amRNSInvestee Company Update
3rd Mar 20165:15 pmRNSInvestee Company Update: Vemo
19th Feb 20167:00 amRNSGrant of Options
18th Feb 20168:21 amRNSHolding(s) in Company
15th Feb 20165:23 pmRNSTransaction in Own Shares
15th Feb 20161:26 pmRNSFurther Investment in Yooya
12th Feb 20165:19 pmRNSCompletion Placing
8th Feb 20166:20 pmRNSPlacing Update
2nd Feb 20167:00 amRNSInvestee Company Update
28th Jan 20167:00 amRNSPlacing
27th Jan 20164:47 pmRNSLorne Abony Appointed as Chief Executive Officer
26th Jan 20167:00 amRNSInvestment
11th Jan 20164:27 pmRNSHolding(s) in Company
11th Jan 201612:33 pmRNSInvestment in Yooya Media
6th Jan 20161:47 pmRNSDirectorate Change
5th Jan 20165:19 pmRNSCompletion of investment in VEMO and Placing
29th Dec 20157:00 amRNSNew Website
22nd Dec 20153:08 pmRNSPlacing and Director Dealing
21st Dec 20155:56 pmRNSAcquisition of shares in Vemo Education, Inc
17th Dec 20154:00 pmRNSDBC receives US FDA approval to market PulseFlowDF
17th Dec 20157:00 amRNSInvestee Company Update - Vemo Education Inc
2nd Dec 20154:26 pmRNSHolding(s) in Company
26th Nov 201511:02 amRNSPlacing
25th Nov 20157:00 amRNSInvestee Company Update - Vemo Education Inc
23rd Nov 20156:05 pmRNSHolding(s) in Company
23rd Nov 201511:36 amRNSResult of General Meeting
23rd Nov 20157:00 amRNSAcquisition
13th Nov 20157:00 amRNSHalf Yearly Report
10th Nov 20151:32 pmRNSPlacing
3rd Nov 20157:00 amRNSProposed Name Change
29th Oct 20157:00 amRNSCorporate Update
22nd Oct 20153:35 pmRNSInvestee company Intensity Therapeutics update
14th Oct 20157:53 amRNSInvestment in Factom
6th Oct 20158:03 amRNSInvestment in Intensity Therapeutics Inc
21st Sep 20157:00 amRNS10% Acquired of nanopayment developer SatoshiPay
18th Sep 201510:32 amRNSResult of AGM
8th Sep 20157:00 amRNSIssue of Equity
7th Sep 20157:00 amRNSAcquisition
1st Sep 20157:03 amRNSIssue of Equity
31st Jul 20158:24 amRNSUpdate on Investment review
28th Jul 201511:36 amRNSResult of EGM
13th Jul 20158:00 amRNSChange of Investing Policy and Name
13th Jul 20157:00 amRNSDirectorate Change
23rd Jun 20152:36 pmRNSNotice of AGM
17th Jun 20159:34 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.